{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T10:49:11Z","timestamp":1767178151407,"version":"build-2238731810"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T00:00:00Z","timestamp":1598313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T00:00:00Z","timestamp":1598313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32 CA009501"],"award-info":[{"award-number":["T32 CA009501"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1245\/s10434-020-08993-7","type":"journal-article","created":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T14:03:32Z","timestamp":1598364212000},"page":"1109-1117","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Primary Tumor Location and Outcomes After Cytoreductive Surgery and Intraperitoneal Chemotherapy for Peritoneal Metastases of Colorectal Origin"],"prefix":"10.1245","volume":"28","author":[{"given":"Mohammad","family":"Adileh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan B.","family":"Yuval","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry S.","family":"Walch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walid K.","family":"Chatila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rona","family":"Yaeger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Garcia-Aguilar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaus","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip B.","family":"Paty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Cercek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garrett M.","family":"Nash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,25]]},"reference":[{"issue":"1","key":"8993_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7\u201334.","journal-title":"CA Cancer J Clin."},{"issue":"8","key":"8993_CR2","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1093\/annonc\/mdx119","volume":"28","author":"N Boeckx","year":"2017","unstructured":"Boeckx N, Koukakis R, OpdeBeeck K, et al. Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies. Ann Oncol. 2017;28(8):1862\u20138.","journal-title":"Ann Oncol."},{"issue":"2","key":"8993_CR3","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/jamaoncol.2016.3777","volume":"3","author":"KK Ciombor","year":"2017","unstructured":"Ciombor KK, Goldberg RM. Primary tumor sidedness as prognostic and predictive biomarker in metastatic colorectal cancer: further validation of a potentially practice-changing variable. JAMA Oncol. 2017;3(2):165\u20136.","journal-title":"JAMA Oncol."},{"issue":"62","key":"8993_CR4","doi-asserted-by":"publisher","first-page":"105749","DOI":"10.18632\/oncotarget.22396","volume":"8","author":"DP Modest","year":"2017","unstructured":"Modest DP, Stintzing S, von Weikersthal LF, et al. Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306). Oncotarget. 2017;8(62):105749\u201360.","journal-title":"Oncotarget."},{"issue":"3","key":"8993_CR5","doi-asserted-by":"publisher","first-page":"e171","DOI":"10.1016\/j.clcc.2016.09.010","volume":"16","author":"Y Sunakawa","year":"2017","unstructured":"Sunakawa Y, Ichikawa W, Tsuji A, et al. Prognostic impact of primary tumor location on clinical outcomes of metastatic colorectal cancer treated with cetuximab plus oxaliplatin-based chemotherapy: a subgroup analysis of the JACCRO CC-05\/06 trials. Clin Colorectal Cancer. 2017;16(3):e171\u201380.","journal-title":"Clin Colorectal Cancer."},{"issue":"2","key":"8993_CR6","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1001\/jamaoncol.2016.3797","volume":"3","author":"S Tejpar","year":"2017","unstructured":"Tejpar S, Stintzing S, Ciardiello F, et al. Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA Oncol. 2017;3(2):194\u2013201.","journal-title":"JAMA Oncol."},{"issue":"33","key":"8993_CR7","doi-asserted-by":"publisher","first-page":"4401","DOI":"10.1200\/JCO.2011.36.4414","volume":"29","author":"JM Weiss","year":"2011","unstructured":"Weiss JM, Pfau PR, O\u2019Connor ES, et al. Mortality by stage for right- versus left-sided colon cancer: analysis of surveillance, epidemiology, and end results\u2014medicare data. J Clin Oncol. 2011;29(33):4401\u20139.","journal-title":"J Clin Oncol."},{"issue":"5","key":"8993_CR8","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1245\/s10434-019-07164-7","volume":"26","author":"GW Ha","year":"2019","unstructured":"Ha GW, Kim JH, Lee MR. Oncologic effects of primary tumor-sidedness on patients with stages 1-3 colon cancer: a meta-analysis. Ann Surg Oncol. 2019;26(5):1366\u201375.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"8993_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/DCR.0b013e3181c703a4","volume":"53","author":"F Benedix","year":"2010","unstructured":"Benedix F, Kube R, Meyer F, et al. Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rectum. 2010;53(1):57\u201364.","journal-title":"Dis Colon Rectum."},{"issue":"6","key":"8993_CR10","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1136\/gutjnl-2011-300865","volume":"61","author":"M Yamauchi","year":"2012","unstructured":"Yamauchi M, Morikawa T, Kuchiba A, et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut. 2012;61(6):847\u201354.","journal-title":"Gut."},{"issue":"10","key":"8993_CR11","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1093\/annonc\/mdu275","volume":"25","author":"E Missiaglia","year":"2014","unstructured":"Missiaglia E, Jacobs B, D\u2019Ario G, et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol. 2014;25(10):1995\u20132001.","journal-title":"Ann Oncol."},{"issue":"3","key":"8993_CR12","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.ejso.2014.11.001","volume":"41","author":"GH Lee","year":"2015","unstructured":"Lee GH, Malietzis G, Askari A, Bernardo D, Al-Hassi HO, Clark SK. Is right-sided colon cancer different to left-sided colorectal cancer? A systematic review. Eur J Surg Oncol. 2015;41(3):300\u20138.","journal-title":"Eur J Surg Oncol."},{"issue":"23","key":"8993_CR13","doi-asserted-by":"publisher","first-page":"5294","DOI":"10.1158\/1078-0432.CCR-15-0527","volume":"21","author":"FA Sinicrope","year":"2015","unstructured":"Sinicrope FA, Mahoney MR, Yoon HH, et al. Analysis of molecular markers by anatomic tumor site in stage III colon carcinomas from adjuvant chemotherapy trial NCCTG N0147 (Alliance). Clin Cancer Res. 2015;21(23):5294\u2013304.","journal-title":"Clin Cancer Res."},{"key":"8993_CR14","doi-asserted-by":"crossref","unstructured":"Yaeger R, Chatila WK, Lipsyc MD, et al. Clinical sequencing defines the genomic landscape of metastatic colorectal cancer. Cancer Cell. 2018;33(1):125\u201336 e123.","DOI":"10.1016\/j.ccell.2017.12.004"},{"issue":"7","key":"8993_CR15","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1245\/s10434-019-07373-0","volume":"26","author":"NV Kotha","year":"2019","unstructured":"Kotha NV, Baumgartner JM, Veerapong J, et al. Primary tumor sidedness is predictive of survival in colon cancer patients treated with cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy: A US HIPEC collaborative study. Ann Surg Oncol. 2019;26(7):2234\u201340.","journal-title":"Ann Surg Oncol."},{"key":"8993_CR16","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","volume":"82","author":"P Jacquet","year":"1996","unstructured":"Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359\u201374.","journal-title":"Cancer Treat Res."},{"issue":"3","key":"8993_CR17","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","volume":"17","author":"DT Cheng","year":"2015","unstructured":"Cheng DT, Mitchell TN, Zehir A, et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn. 2015;17(3):251\u2013264.","journal-title":"J Mol Diagn."},{"key":"8993_CR18","doi-asserted-by":"crossref","unstructured":"Chakravarty D, Gao J, Phillips SM, et al. OncoKB: A precision oncology knowledge base. JCO Precis Oncol. 2017;2017.","DOI":"10.1200\/PO.17.00011"},{"key":"8993_CR19","unstructured":"Sanchez-Vega F, Mina M, Armenia J, et al. Oncogenic signaling pathways in the cancer genome atlas. Cell. 2018;173(2):321\u2013337 e310."},{"issue":"12","key":"8993_CR20","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/S1470-2045(16)30500-9","volume":"17","author":"J Franko","year":"2016","unstructured":"Franko J, Shi Q, Meyers JP, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol. 2016;17(12):1709-1719.","journal-title":"Lancet Oncol."},{"key":"8993_CR21","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ejca.2015.09.017","volume":"53","author":"PH Cashin","year":"2016","unstructured":"Cashin PH, Mahteme H, Spang N, et al. Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: a randomised trial. Eur J Cancer. 2016;53:155\u2013162.","journal-title":"Eur J Cancer."},{"issue":"16","key":"8993_CR22","doi-asserted-by":"publisher","first-page":"3756","DOI":"10.1002\/cncr.25116","volume":"116","author":"J Franko","year":"2010","unstructured":"Franko J, Ibrahim Z, Gusani NJ, Holtzman MP, Bartlett DL, Zeh HJ, 3rd. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer. 2010;116(16):3756\u201362.","journal-title":"Cancer."},{"issue":"1","key":"8993_CR23","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1200\/JCO.2009.23.9285","volume":"28","author":"D Elias","year":"2010","unstructured":"Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28(1):63\u20138.","journal-title":"J Clin Oncol."},{"issue":"9","key":"8993_CR24","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1245\/s10434-008-9966-2","volume":"15","author":"VJ Verwaal","year":"2008","unstructured":"Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15(9):2426\u201332.","journal-title":"Ann Surg Oncol."},{"issue":"16","key":"8993_CR25","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1200\/JCO.2004.10.012","volume":"22","author":"O Glehen","year":"2004","unstructured":"Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22(16):3284\u201392.","journal-title":"J Clin Oncol."},{"issue":"6","key":"8993_CR26","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.jamcollsurg.2006.08.024","volume":"203","author":"RG da Silva","year":"2006","unstructured":"da Silva RG, Sugarbaker PH. Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. J Am Coll Surg. 2006;203(6):878\u201386.","journal-title":"J Am Coll Surg."},{"issue":"2","key":"8993_CR27","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1016\/j.clcc.2016.02.007","volume":"15","author":"HL Wong","year":"2016","unstructured":"Wong HL, Lee B, Field K, et al. Impact of primary tumor site on bevacizumab efficacy in metastatic colorectal cancer. Clin Colorectal Cancer. 2016;15(2):e9\u2013e15.","journal-title":"Clin Colorectal Cancer."},{"key":"8993_CR28","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1186\/s12885-016-2358-2","volume":"16","author":"KH Chen","year":"2016","unstructured":"Chen KH, Shao YY, Chen HM, et al. Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study. BMC Cancer. 2016;16:327.","journal-title":"BMC Cancer."},{"issue":"8","key":"8993_CR29","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1093\/annonc\/mdx175","volume":"28","author":"D Arnold","year":"2017","unstructured":"Arnold D, Lueza B, Douillard JY, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol. 2017;28(8):1713\u201329.","journal-title":"Ann Oncol."},{"issue":"1","key":"8993_CR30","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1001\/jamasurg.2017.3466","volume":"153","author":"MA Aljehani","year":"2018","unstructured":"Aljehani MA, Morgan JW, Guthrie LA, et al. Association of primary tumor site with mortality in patients receiving bevacizumab and cetuximab for metastatic colorectal cancer. JAMA Surg. 2018;153(1):60\u20137.","journal-title":"JAMA Surg."},{"key":"8993_CR31","doi-asserted-by":"crossref","unstructured":"Cremolini C, Antoniotti C, Lonardi S, et al. Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Ann Oncol. 2018.","DOI":"10.1093\/annonc\/mdy140"},{"issue":"5","key":"8993_CR32","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1245\/s10434-019-07209-x","volume":"26","author":"D Shida","year":"2019","unstructured":"Shida D, Tanabe T, Boku N, et al. Prognostic value of primary tumor sidedness for unresectable stage IV colorectal cancer: a retrospective study. Ann Surg Oncol. 2019;26(5):1358\u201365.","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"8993_CR33","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1245\/s10434-017-6264-x","volume":"25","author":"JM Creasy","year":"2018","unstructured":"Creasy JM, Sadot E, Koerkamp BG, et al. The impact of primary tumor location on long-term survival in patients undergoing hepatic resection for metastatic colon cancer. Ann Surg Oncol. 2018;25(2):431\u20138.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"8993_CR34","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ejso.2017.10.218","volume":"44","author":"A Dupre","year":"2018","unstructured":"Dupre A, Malik HZ, Jones RP, Diaz-Nieto R, Fenwick SW, Poston GJ. Influence of the primary tumour location in patients undergoing surgery for colorectal liver metastases. Eur J Surg Oncol. 2018;44(1):80\u20136.","journal-title":"Eur J Surg Oncol."},{"issue":"18","key":"8993_CR35","doi-asserted-by":"publisher","first-page":"LBA3503","DOI":"10.1200\/JCO.2018.36.18_suppl.LBA3503","volume":"36","author":"F Quenet","year":"2018","unstructured":"Quenet F, Elias D, Roca L, et al. A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. J Clin Oncol. 2018;36(18):LBA3503.","journal-title":"J Clin Oncol."}],"updated-by":[{"DOI":"10.1245\/s10434-020-09191-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000}}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-08993-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-020-08993-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-08993-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T18:06:10Z","timestamp":1668017170000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-020-08993-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,25]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["8993"],"URL":"https:\/\/doi.org\/10.1245\/s10434-020-08993-7","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,25]]},"assertion":[{"value":"10 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the original article there is a reference missing, in addition to its citations in the text. The reference is as follows.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Yaeger has received research funding from Array BioPharma, Genentech, GlaxoSmithKline, and Novartis and has served as an advisory board member for GlaxoSmithKline. Dr. Garcia-Aguilar has received fees from Medtronic, Johnson and Johnson, and Intuitive Surgical. Dr. Cercek is an employee\/paid consultant for Bayer and Proteus and reports receiving commercial research grants from Seattle Genetics. Dr. Nash has received meal reimbursement from Intuitive Surgical.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}